Evidence map›Paper›PMID 41170472›Full record

ArticleFrontiers in public health2025

Consolidation of a genomic epidemiological surveillance network for tuberculosis (REVIGET) in northern and northeastern Brazil: a study protocol.

Emilyn Costa Conceição, Karla Valéria Batista Lima, Cristiane Cunha Frota, Theolis Costa Barbosa Bessa, Adriana Ayden Ferreira, Abhinav Sharma, Davi Josué Marcon, Layana Rufino Ribeiro, Alex Brito Souza, Danna Karen Corrêa Dos Santos and 11 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Emilyn Costa Conceição *South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Karla Valéria Batista Lima *Secao de Bacteriologia do Instituto Evandro Chagas, Ananindeua, Brazil.
Cristiane Cunha FrotaDepartamento de Patologia, Universidade Federal do Ceara, Fortaleza, Brazil.
Theolis Costa Barbosa BessaRede Brasileira de Pesquisas em Tuberculose, Rio de Janeiro, Brazil.
Adriana Ayden FerreiraLaboratorio Central do Amazonas, Fundacao de Vigilancia em Saude do Amazonas Dra Rosemary Costa Pinto, Manaus, Amazonas, Brazil.
Abhinav SharmaSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Davi Josué MarconSecao de Bacteriologia do Instituto Evandro Chagas, Ananindeua, Brazil.
Layana Rufino RibeiroSecao de Bacteriologia do Instituto Evandro Chagas, Ananindeua, Brazil.
Alex Brito SouzaSecao de Bacteriologia do Instituto Evandro Chagas, Ananindeua, Brazil.
Danna Karen Corrêa Dos SantosSecao de Bacteriologia do Instituto Evandro Chagas, Ananindeua, Brazil.
Carlos Augusto Abreu AlberioHospital Universitário Joao de Barros Barreto da Universidade Federal do Para, Belem, Brazil.
Ricardo José de Paula Souza E GuimarãesPrograma de Pos-graduacao em Epidemiologia e Vigilancia em Saude, Instituto Evandro Chagas, Ananindeua, Brazil.
Ismari Perini FurlanetoCentro Universitario do Para, Belem, Brazil.
Lilian Eduarda de Oliveira FreitasLaboratorio Central do Amazonas, Fundacao de Vigilancia em Saude do Amazonas Dra Rosemary Costa Pinto, Manaus, Amazonas, Brazil.
Emmily Oliveira AmadorSecao de Bacteriologia do Instituto Evandro Chagas, Ananindeua, Brazil.
Hendor Neves Ribeiro de JesusInstituto Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, Bahia, Brazil.
Leonardo Bruno Paz Ferreira BarretoLaboratorio de Bacteriologia e Bioensaios em Micobacterias, Instituto Nacional de Infectologia Evandro Chagas, Fundacao Oswaldo Cruz, Manguinhos, Rio de Janeiro, Brazil.
Maria Cristina Silva LourençoLaboratorio de Bacteriologia e Bioensaios em Micobacterias, Instituto Nacional de Infectologia Evandro Chagas, Fundacao Oswaldo Cruz, Manguinhos, Rio de Janeiro, Brazil.
Tulio de OliveiraCentre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.
Robin Mark WarrenSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
REVIGET Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, tuberculosis (TB) remains a top cause of death from infectious diseases, with an estimated 1.5 million deaths annually. Given its substantial social and economic burden, TB is a priority in the United Nations 2030 Agenda for Sustainable Development. The WHO's End TB Strategy emphasizes research, innovation, and the rapid implementation of new technologies, such as whole-genome sequencing (WGS), which are pivotal for precision health approaches and drug-resistant TB (DR-TB) surveillance. This study aims to strengthen genomic TB surveillance in the North and Northeast Brazilian regions by applying WGS to study DR-TB cases, training professionals in genomics and bioinformatics, and deploying a national surveillance platform (GEMIBRA). This is an observational, cross-sectional, prospective, quantitative, and qualitative study to be conducted in the states of Pará, Amazonas, Ceará, and Bahia. A total of 500

Indexed as

Epidemiological MonitoringGenomicsMycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantBrazilCross-Sectional StudiesHumansObservational Studies as TopicProspective StudiesWhole Genome SequencingBrazilcapacity buildingdrug-resistant tuberculosisgenomic surveillancewhole-genome sequencing

Identifiers

PMID41170472
PMCPMC12568509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.